The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Sponsor: Astellas Pharma Inc
A PHASE2 clinical study on Mucormycosis, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2023 [monthly]
Completed PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Gilead Sciences
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .